Leukemia, Lymphoid Malignancy (Lymphoma and CLL), Lymphoma, Solid Tumor Malignancy
Conditions
Brief summary
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
Interventions
DRUGSNX-5422 Mesylate Hsp90 inhibitor
dose escalated, tablets twice a week; undetermined duration until disease progression
Sponsors
National Cancer Institute (NCI)
Esanex Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Solid tumors or lymphoid malignancies refractory to standard therapy * measurable disease * recovery to Grade \< 1 toxicity due to prior adverse event or chemotherapy * no chemotherapy within 4 weeks of entering study * Age \> 18 years * Karnofsy \>= 60% * Life expectancy \> 3 months * normal or adequate organ and marrow function
Exclusion criteria
* receiving other investigational agents * brain metastases * uncontrolled medical illness * HIV+ receiving combination antiretroviral therapy * significant GI disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MTD, safety and toxicity | continuous |
Secondary
| Measure | Time frame |
|---|---|
| pharmacokinetic profile of SNX-5422 | first cycle |
| tumor response measured by X-rays or scans | after every 2 cycles |
Countries
United States
Outcome results
None listed